Adverse Event Management Team, Post-vaccination Management Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea
© 2021 Korea Disease Control and Prevention Agency
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Variable | Vaccination doses (n=3,586,814) | Adverse events reported |
p-value |
|||
---|---|---|---|---|---|---|
Non-serious adverse events |
Serious adverse events |
|||||
Death (n=73) | Anaphylaxis (n=173) | Others (n=292) | ||||
Sex | <0.001 | |||||
Male | 1,307,450 (36.5) | 2,968 (19.0) | 38 (52.1) | 30 (17.3) | 97 (33.2) | |
Female | 2,279,364 (63.5) | 12,690 (81.0) | 35 (47.9) | 143 (82.7) | 195 (66.8) | |
Age (y) | <0.001 | |||||
18–29 | 180,115 (5.0) | 5,198 (33.2) | 1 (1.4) | 35 (20.2) | 33 (11.3) | |
30–49 | 698,354 (19.5) | 5,583 (35.7) | 1 (1.4) | 88 (50.9) | 75 (25.7) | |
50–74 | 939,634 (26.2) | 3,499 (22.3) | 15 (20.5) | 31 (17.9) | 80 (27.4) | |
≥75 | 1,768,711 (49.3) | 1,378 (8.8) | 56 (76.7) | 19 (11.0) | 104 (35.6) | |
AstraZeneca vaccine | NA | |||||
1st dose | 1,807,921 (50.4) | 13,585 (86.8) | 44 (60.3) | 139 (80.3) | 200 (68.5) | |
2nd dose | 186 (0.01) | 0 | 0 | 0 | 0 | |
Pfizer-BioNTech | <0.001 | |||||
1st dose | 1,550,412 (43.2) | 1,471 (9.4) | 28 (38.4) | 33 (19.1) | 87 (29.8) | |
2nd dose | 228,295 (6.4) | 602 (3.8) | 1 (1.4) | 1 (0.6) | 5 (1.7) |
NA, not available. Data were calculated using information and suspected adverse events after coronavirus disease 2019 (COVID-19) vaccination reported by medical facilities or doctors. The results do not suggest causality between the vaccines and adverse events. Non-serious adverse events include the following: common symptoms such as redness at the site of injection, pain, swelling, myalgia, fever, headache, chills, and others. Serious adverse events include the following: death, suspected anaphylaxis, major adverse events (adverse events of special interest, admission to the intensive care unit, life-threatening events, permanent disability/sequelae, and others). Chi-square (Pearson or Fisher exact) test of proportion of serious/non-serious adverse events by groups.